Announcements - OBI Pharma 台灣浩鼎

2019.May.06

Letter received from National Medical Products Administration (NMPA) of China regarding Adagloxad Simolenin (OBI-822) Phase III clinical study to be resubmitted after supplementation

2019.Apr.22

Supplementary announcement for the company to issue ordinary shares through rights offering

2019.Apr.19

Supplementary announcement for 2019 Annual General Meeting

2019.Apr.18

Announcement for the company to issue ordinary shares through rights offering and bank designated for collection and deposition

2019.Apr.13

Clearance of Adagloxad Simolenin (OBI-822) for a Phase III clinical study by Ministry of Health of the Russian Federation

2019.Apr.09

Announcement for the company to issue ordinary shares through rights offering

2019.Mar.27

Announcement of capital change registration for the treasury share retirement

2019.Mar.08

The board of directors have resolved not to distribute dividends for 2018

2019.Mar.08

The Board of Directors resolved to hold 2019 Annual General Meeting

2019.Mar.08

Change of accountant due to internal adjustment of the accounting firm

News

Latest News

Events

Latest events